EyePoint Pharmaceuticals has announced the execution of a license agreement with Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau and Taiwan.

This agreement expands the collaboration between EyePoint and Equinox Sciences, LLC, a Betta Pharmaceuticals affiliate, which was established in February 2020.

Under the terms of the new agreement between EyePoint and Betta Pharmaceuticals, which were previously contemplated under the February 2020 vorolanib license agreement between EyePoint and Equinox Sciences, Betta Pharmaceuticals receives exclusive rights to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan (the Territory). EyePoint will retain global ophthalmic rights for EYP-1901 in the rest of the world.

Concurrently, EyePoint and Equinox Sciences have executed an amendment to their February 2020 license agreement, expanding EyePoint’s exclusive rights to develop and commercialize vorolanib, a tyrosine kinase inhibitor, through localized delivery for the treatment of all ophthalmic diseases, including DME, outside of the Territory.

EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration (wet AMD), combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.